deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 NaN [NaN; NaN] /10000
0/0 vs. 0/0
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0